Antiangiogenic treatment in hepatocellular carcinoma: The balance of efficacy and safety

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 337-347

  Welker, Martin Walter ^a   Trojan, Joerg ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antiangiogenesis; HCC; MET; Sorafenib; TACE

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; CAPECITABINE; CETUXIMAB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; IMATINIB; LAPATINIB; LINIFANIB; MITOMYCIN; OBLIMERSEN; OCTREOTIDE; ORANTINIB; OXALIPLATIN; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; RAPAMYCIN; SELUMETINIB; SORAFENIB; SUNITINIB; TIVANTINIB; TREBANANIB; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ABDOMINAL PAIN; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DIARRHEA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOXEMIA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; LUNG NON SMALL CELL CANCER; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEINURIA; RASH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; THROMBOEMBOLISM; TUMOR GROWTH; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 84885926936     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S35029     Document Type: Review

References (135)

1. El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576.
2. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatolog y. 2002;35:519-524.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
4. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classifcation. Semin Liver Dis. 1999;19:329-338.
5. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol. 2012;30:4026-4034.
6. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the nonin-vasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97-104.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
8. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835-844.
9. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocel-lular carcinoma. Oncogene. 2006;25:3866-3884.
10. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterolog y. 2004;127:S179-S188.
11. Llovet JM, Bruix J. Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization. Radiology. 2004;230:300-301.
12. De Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol. 2012;56 Suppl:S75-S87.
13. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol. 2009;50:604-620.
14. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008;49:523-529.
15. Moon WS, Rhyu KH, Kang MJ, et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol. 2003;16:552-557.
16. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998;28:68-77.
17. Chao Y, Li C P, Chau GY, et al. Prognostic signifcance of vascular endothelial growth factor, basic fbroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol. 2003;10:355-362.
18. Poon RT, Lau C P, Ho J W, Yu WC, Fan ST, Wong J. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res. 2003;9:5339-5345.
19. Poon RT, Ho J W, Tong CS, Lau C, Ng IO, Fan ST. Prognostic signifcance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004;91:1354-1360.
20. Torimura T, Ueno T, Kin M, et al. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol. 2004;40:799-807.
21. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepa-tocellular carcinoma. N Engl J Med. 2008;359:378-390.
22. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293-4300.
23. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008;99:159-165.
24. Ya u T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer. 2009;115:428-436.
25. Worns MA, Weinmann A, Pfngst K, et al. Safety and effcacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol. 2009;43:489-495.
26. Welker MW, Lubomierski N, Gog C, et al. Effcacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. J Chemother. 2010;22:205-211.
27. Rimassa L, Pressiani T, Boni C, et al. A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma. Oncologist. 2013;18:379-380.
28. Cheng A, Kang Y, Lin D, et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2011;29 Suppl:4000.
29. Cainap C, Qin S, Huang WT, et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2013;31 Suppl:249.
30. French DM, Lin BC, Wang M, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PloS One. 2012;7:e36713.
31. Cai Z, Zhang Y, Borzilleri RM, et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fuoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f] [1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fbroblast growth fa. J Med Chem. 2008;51:1976-1980.
32. Finn RS, Kang YK, Mulcahy M, et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18:2090-2098.
33. Park J W, Finn RS, Kim JS, et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2011;17:1973-1983.
34. Llovet JM, Decaens T, Raoul JL, et al. Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study. J Hepatol. 2012;56 Suppl:S549.
35. Johnson P, Qin S, Park J W, et al. Brivanib (BRI) versus sorafenib (SOR) as first-line therapy in patients with unrespectable, advanced hepatocellular carcinoma (HCC): results from the phase 3 BRISK-FL study. Hepatology. 2012;56 Suppl:1519-1520.
36. Ross MA, Sander CM, Kleeb TB, Watkins SC, Stolz DB. Spatiotemporal expression of angiogenesis growth factor receptors during the revascularization of regenerating rat liver. Hepatology. 2001;34:1135-1148.
37. Vogl TJ, Naguib NN, Nour-Eldin NE, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol. 2009;72:505-516.
38. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739.
39. Poon RT, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep. 2004;11:1077-1084.
40. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004;10:2878-2882.
41. Shim JH, Park JW, Kim JH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 2008;99:2037-2044.
42. Leelawat K, Laisupasin P, Kiatdilokrut A, et al. The effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after tran-scatheter arterial chemoembolization (TACE). J Med Assoc Thai. 2008;91:1539-1543.
43. Xiong Z P, Yang SR, Liang ZY, et al. Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2004;3:386-390.
44. Seki T, Tamai T, Ikeda K, et al. Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol. 2001;13:291-294.
45. Erhardt A, Kolligs FT, Dollinger M, et al. First-in-men demonstration of sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma - interim analysis of the SOCRATES trial. Hepatology. 2009;50 Suppl:A1080.
46. Park J W, Koh YH, Kim HB, et al. Phase II study of concurrent transar-terial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol. 2012;56:1336-1342.
47. Duan F, Wang MQ, Liu FY, Wang ZJ, Song P, Wang Y. Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis. Asia Pac J Clin Oncol. 2012;8:156-163.
48. Tan W F, Qiu ZQ, Yu Y, et al. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin. 2010;31:1643-1648.
49. Qu XD, Chen CS, Wang JH, et al. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer. 2012;12:263.
50. Chung YH, Han G, Yoon JH, et al. Interim analysis of START: study in Asia of the combination of TACE (transcatheter arterial chemoem-bolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer. 2013;132:2448-2458.
51. Bai W, Wang YJ, Zhao Y, et al. Sorafenib in combination with tran-sarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. J Dig Dis. 2013;14:181-190.
52. Han G, Yang J, Shao G, et al. Sorafenib in combination with transarte-rial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. Future Oncol. 2013;9:403-410.
53. Zhao Y, Wang WJ, Guan S, et al. Sorafenib combined with transarte-rial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol. 2013;24:1786-1792.
54. Dufour JF, Hoppe H, Heim MH, et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist. 2010;15:1198-1204.
55. Gao S, Yang Z, Zheng Z, et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology. 2013;60.
56. Reyes DK, Azad N, Kamel IR, et al. Phase II trial of sorafenib combined with doxorubicin eluting bead-transarterial chemoembolization (DEB-TACE) for patients with hepatocellular carcinoma (HCC): interim safety and efficacy analysis. Hepatology. 2009;50 Suppl:6A-7A.
57. Lencioni R, Llovet J, Han G, et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. J Clin Oncol. 2012;30 Suppl:LBA154.
58. Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocel-lular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol. 2012;56:1330-1335.
59. Gerald D, Chintharlapalli S, Augustin H, Benjamin L. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013;73:1649-1657.
60. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225:1-26.
61. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 2002;109: 863-867.
62. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12: 89-103.
63. Kondo S, Ojima H, Tsuda H, et al. Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol. 2013;18:207-213.
64. Kaposi-Novak P, Lee JS, Gòmez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 2006;116:1582-1595.
65. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology. 1997;25:619-623.
66. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29:4989-5005.
67. Welker M W, Trojan J. Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives. Word J Gastroenterol. 2011;17:3075-3081.
68. O'Neil BH, Williams-Goff LW, Kauh J, et al. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. J Clin Oncol. 2009;27 Suppl:e15574.
69. Schwartz JD, Schwartz M, Lehrer D, et al. Bevacizumab in unresect-able hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J Clin Oncol. 2006; 24:4144.
70. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unrespectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992-2998.
71. Boige V, Malka D, Bourredjem A, et al. Efficacy, safety, and biomark-ers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012;17:1063-1072.
72. Kim G P, Mahoney MR, Szydlo D, et al. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs. 2012;30:387-394.
73. Gruenwald V, Wilkens L, Gebel M, et al. A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. J Clin Oncol. 2007;25 Suppl:4598.
74. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetux-imab in patients with advanced hepatocellular carcinoma. Cancer. 2007;110:581-589.
75. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23:6657-6663.
76. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. 2007;110:1059-1067.
77. Shiah HS, Chen CY, Dai C Y, et al. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2013;37:62-73.
78. Zhu AX, Abrams TA, Miksad R, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011;117:5094-5102.
79. O'Dwyer PJ, Giantonio BJ, Levy DE, Fitzgerald DB, Benson AB. Geftinib in advanced unrespectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's study E1203. J Clin Oncol. 2006;24 Suppl:4143.
80. Lin AY, Fisher GA, So S, Tang C, Levitt L. Phase II study of ima-tinib in unresectable hepatocellular carcinoma. Am J Clin Oncol. 2008;31:84-88.
81. Bekaii-Saab T, Markowitz J, Prescott N, et al. A multi-institutional phase II study of the effcacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009;15: 5895-5901.
82. Ramanathan RK, Belani C P, Singh DA, et al. A phase II study of lapa-tinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009;64:777-783.
83. Toh HC, Chen PJ, Carr BI, et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer. 2013;119:380-387.
84. Rizell M, Andersson M, Cahlin C, Hafstrom L, Olausson M, Lindner P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol. 2008;13:66-70.
85. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
86. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after tran-sarterial chemoembolisation in Japanese and Korean patients with unre-sectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117-2127.
87. Hoda D, Catherine C, Strosberg J, et al. Phase II study of sunitinib malate in adult pts (pts) with metastatic or surgically unresectable hepatocellular carcinoma (HCC). Presented at: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL.
88. Zhu AX, Sahani D V, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27:3027-3035.
89. Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009;10:794-800.
90. Koeberle D, Montemurro M, Samaras P, et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15:285-292.
91. Wörns MA, Schuchmann M, Düber C, Otto G, Galle PR, Weinmann A. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology. 2010;79:85-92.
92. Barone C, Basso M, Biolato M, et al. A phase II study of suni-tinib in advanced hepatocellular carcinoma. Dig Liver Dis. Epub February 11, 2013.
93. Pinter M, Wichlas M, Schmid K, et al. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. Eur J Gastroenterol Hepatol. 2008;20:1012-1019.
94. Santoro A, Simonelli M, Rodriguez-Lope C, et al. A phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer. 2013;108:21-24.
95. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14:55-63.
96. Kanai F, Yoshida H, Tateishi R, et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2011;67:315-324.
97. Hsu C, Yang TS, Huo TI, et al. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. J Hepatol. 2012;56:1097-1103.
98. Britten CD, Gomes AS, Wainberg ZA, et al. Transarterial chemoem-bolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer. 2012;12:16.
99. Buijs M, Reyes DK, Pawlik TM, et al. Phase 2 trial of concurrent beva-cizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2013;119: 1042-1049.
100. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind J-FH. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011;29:3960-3967.
101. Cabrera R, Pannu DS, Caridi J, et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2011;34:205-213.
102. Chow PK, Poon D, Win KM, et al. Multicenter phase II study of SIR-sphere plus sorafenib as first-line treatment in patients with nonresectable hepatocellular carcinoma: the Asia-Pacific Hepatocel-lular Carcinoma Trials Group Protocol 05 (AHCC05). J Clin Oncol. 2010;28 Suppl:4072.
103. Erhardt A, Kolligs FT, Dollinger M, et al. Sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma - final results of the SOCRATES trial. J Clin Oncol. 2011;29 Suppl:4107.
104. Wu JB, Xu GJ, Lu YS, et al. Efficacy of transcatheter arterial chemoembolization (TACE) combined with sorafenib in the treatment of advanced hepatocellular carcinoma. Afr J Pharm Pharmacol. 2012;6:2515-2519.
105. Sieghart W, Pinter M, Reisegger M, et al. Conventional transarte-rial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. Eur Radiol. 2012;22: 1214-1223.
106. Hsu CH, Yang TS, Hsu C, et al. Effcacy and tolerability of bevaci-zumab plus capecitabine as frst-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010;102:981-986.
107. Sun W, Sohal D, Haller DG, et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer. 2011;117:3187-3192.
108. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27:843-850.
109. Kaseb AO, Garrett-Mayer E, Morris JS, et al. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology. 2012;82:67-74.
110. Yau T, Wong H, Chan P, et al. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs. 2012;30: 2384-2390.
111. Philip PA, Mahoney MR, Holen KD, et al. Phase 2 study of bevaci-zumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer. 2012;118:2424-2430.
112. Govindarajan R, Siegel E, Makhoul I, Williamson S. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocel-lular carcinoma. Am J Clin Oncol. 2012;36:254-257.
113. Treiber G, Wex T, Schneider G, et al. Treatment of advanced or meta-static hepatocellular cancer (HCC): final clinical results of a single-arm phase II study of bevacizumab and everolimus. J Clin Oncol. 2012; 30 Suppl:4107.
114. Zhu AX, Blaszkowsky LS, Ryan D P, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24: 1898-1903.
115. Berlin JD, Powell ME, Su Y, et al. Bortezomib (B) and doxorubicin (dox) in patients (pts) with hepatocellular cancer (HCC): a phase II trial of the Eastern Cooperative Oncology Group (ECOG 6202) with laboratory correlates. J Clin Oncol. 2008;26 Suppl:4592.
116. Sanoff H, Bernard S, Goldberg R, et al. Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma. Gastrointest Cancer Res. 2011;4:78-83.
117. Louaf S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer. 2007;109:1384-1390.
118. Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer. 2008;112:2733-2739.
119. Chiorean EG, Ramasubbaiah R, Yu M, et al. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist. 2012;17:13.
120. Luelmo S, Osanto S, Weijl N. Phase II study of everolimus and capecit-abine in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). Results of the frst 10 patients included. Ann Oncol. 2012;23 Suppl:1674.
121. Knox JJ, Chen XE, Feld R, et al. A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Invest New Drugs. 2008;26:193-194.
122. Yau T, Chan P, Pang R, Ng K, Fan ST, Poon RT. Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer. 2010;116:5022-5029.
123. Petrini I, Lencioni M, Ricasoli M, et al. Phase II trial of sorafenib in combination with 5-fuorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2012;69:773-780.
124. Richly H, Schultheis B, Adamietz IA, et al. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer. 2009;45: 579-587.
125. Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepa-tocellular carcinoma: a randomized trial. JAMA. 2010;304: 2154-2160.
126. Dima G, Lucia M, La Gattuta G, et al. Perspective phase II study of combination sorafenib plus mitomycin-c in the treatment of advanced hepatocellular carcinoma (HCC). Ann Oncol. 2009;19 Suppl:49.
127. Prete SD, Montella L, Caraglia M, et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II SoLAR study. Cancer Chemother Pharmacol. 2010;66:837-844.
128. Abou-Alfa GK, Chan SL, Lin CC, et al. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2011;68:539-545.
129. Bitzer M, Horger M, Ganten T, et al. Efficacy, safety, toler-ability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC). J Clin Oncol. 2012; 30 Suppl:4115.
130. Shen Y, Shao Y, Hsu C, et al. Phase II study of sorafenib plus tegafur/ uracil (UFT) in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2008;26 Suppl:15664.
131. Hsu CH, Shen YC, Lin ZZ, et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol. 2010;53:126-131.
132. Hsu C, Lin Z, Lee K, et al. A phase II trial of thalidomide plus tegafur/ uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC): fnal report. J Clin Oncol. 2009;27 Suppl:15533.
133. Zhu AX, Fuchs CS, Clark J W, et al. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005;10:392-398.
134. Tai WT, Cheng AL, Shiau CW, et al. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Mol Cancer Ther. 2012;11:452-463.
135. Zhu AX, Rosmorduc O, Evans J, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). Ann Oncol. 2012;23 Suppl:LBA2.